Skip to main content

Table 2 List and frequency of grade ≥3 adverse events

From: Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer

Adverse event

N (%)

Grade

Dyspnea

1 (4.5)

3

Anemia

1 (4.5)

3

Back pain

1 (4.5)

3

Elevated creatinine

1 (4.5)

3

Facial edema around eyes

1 (4.5)

3

Generalized weakness

1 (4.5)

3

Hyperbilirubinemia

2 (9)

3

Hyperglycemia

1 (4.5)

3

Hypoalbuminemia

2 (9)

3

Hypocalcemia

1 (4.5)

3

Hyponatremia

1 (4.5)

3

Hypophosphatemia

1 (4.5)

3

Increased alkaline phosphatase

1 (4.5)

3

Increased lipase

1 (4.5)

3

Leukopenia

2 (9)

3

Neutrophil count decreased

1 (4.5)

3

Pleural effusion

1 (4.5)

3

Hyperbilirubinemia

1 (4.5)

4